- Home
- ACON vs REVB Comparison
ACON vs REVB Comparison
Compare ACON & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACON
- REVB
- Stock Information
- Founded
- ACON 2008
- REVB 2020
- Country
- ACON United States
- REVB United States
- Employees
- ACON N/A
- REVB N/A
- Industry
- ACON Retail: Computer Software & Peripheral Equipment
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- ACON Technology
- REVB Health Care
- Exchange
- ACON Nasdaq
- REVB Nasdaq
- Market Cap
- ACON 1.7M
- REVB 1.4M
- IPO Year
- ACON 2022
- REVB N/A
- Fundamental
- Price
- ACON $0.11
- REVB $0.34
- Analyst Decision
- ACON Buy
- REVB
- Analyst Count
- ACON 2
- REVB 0
- Target Price
- ACON $1.30
- REVB N/A
- AVG Volume (30 Days)
- ACON 991.9K
- REVB 1.7M
- Earning Date
- ACON 11-14-2024
- REVB 11-08-2024
- Dividend Yield
- ACON N/A
- REVB N/A
- EPS Growth
- ACON N/A
- REVB N/A
- EPS
- ACON N/A
- REVB N/A
- Revenue
- ACON $49,289.00
- REVB N/A
- Revenue This Year
- ACON N/A
- REVB N/A
- Revenue Next Year
- ACON $186.36
- REVB N/A
- P/E Ratio
- ACON N/A
- REVB N/A
- Revenue Growth
- ACON N/A
- REVB N/A
- 52 Week Low
- ACON $0.10
- REVB $0.32
- 52 Week High
- ACON $7.39
- REVB $25.26
- Technical
- Relative Strength Index (RSI)
- ACON 30.75
- REVB 27.29
- Support Level
- ACON $0.16
- REVB $0.32
- Resistance Level
- ACON $0.20
- REVB $0.47
- Average True Range (ATR)
- ACON 0.02
- REVB 0.08
- MACD
- ACON -0.01
- REVB -0.02
- Stochastic Oscillator
- ACON 13.37
- REVB 3.40
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).